Take the Money and Run Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: J.B.C. who wrote (14354)	8/9/2002 10:45:33 PM
From: 2MAR$	Read Replies (1) of 17639

CHTT : Manufaturer of "Phisoderm", "Dexatrim" and "Garlique" They make some good CHTT looks like ( must be the Garlique ? ) nice run , fully valued here? ...maybe see mid 20's soon ? certainly has had a nice run... longer term growth stock ? are there any of them in existence ? ? first time ever looking at this one ....300K short shrs very "low float" =8mil Chattem Inc. Ticker: CHTT Page 1 of 10 Complete Financials: May 2002 Exchange NASD FY END NOV ISSUE DATA (08/02/02) PER SHARE DATA RATIOS Price $ 30.40 EPS (TTM) $ 1.32 P/E (TTM) 23.05 52W High $ 36.67 Div. Rate $ 0.00 Yield 0.00 % 52W Low $ 9.52 Book Value $ 6.38 Price/Book 4.77 Shrs Out 9.48 Mil Cash $ 1.88 ROE (TTM) 23.86 % Float 8.10 Mil Rev (TTM) $ 22.57 ROA (TTM) 3.92 % Mon. Vol 2.29 Mil Curr. Ratio 1.66 Beta 1.09 LT Dbt/Eqty 3.92 BRIEF: Chattem, Inc. is a diversified manufacturer and marketer of consumer products. CHTT manufactures and markets branded over the counter pharmaceuticals, toiletries and cosmetics. For the 6 months ended 5/02, sales rose 13% to $107.1M. Net income before extra. item and acctg. change totalled $8M, up from $4M. Results reflect growth in the analgesic product group and the DEXATRIM, GARLIQUE and PHISODERM brands, and the retirement of senior debt. 6/17: 16:41 ET Chattem beats by eight cents; announces 1.8 mln share secondary (CHTT) 35.88 +2.28: Company reports Q2 earnings of $0.58 per share, $0.08 better than the Multex consensus estimate; Q2 revs came in at $63.4 mln vs the consensus estimate of $61.3 mln; sees Q3 sales in the range of $61-$63 mln vs the current consensus estimate of $56.9 mln; sees Q3 earnings in the range of $0.46-$0.48 per share vs the current consensus estimate of $0.50 per share; separately announces it is commencing a public offering of 1.8 million shares

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next